Comparison of Visual Fields: Humphrey Field Analyzer (HFA) SITA Strategy, SCOPE (GATE Strategy) and Humphrey MATRIX Perimeter
X-SCOPE
Detection of Visual Field Defects and Scotoma Progression in Glaucomatous Optic Neuropathy, Using Short-term Intervals With Automated Scotoma-oriented Perimetry (SCOPE) and the Fast Thresholding Strategy GATE (German Adaptive Threshold Estimation)
3 other identifiers
observational
30
1 country
1
Brief Summary
The purpose of this study is to compare three perimetric techniques regarding progression of the visual field.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Nov 2008
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2008
CompletedFirst Submitted
Initial submission to the registry
February 16, 2010
CompletedFirst Posted
Study publicly available on registry
February 17, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2016
CompletedDecember 20, 2016
December 1, 2016
5.1 years
February 16, 2010
December 19, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
glaucoma progression
6 month
Study Arms (1)
open angle glaucoma, glaucoma suspects
risk of progression, Latanoprost monotherapy
Interventions
visual fields
Eligibility Criteria
University Eye Hospital
You may qualify if:
- max. ± 8 dpt sph, max. ± 3 dpt cyl
- distant visual acuity \> 10/20
- isocoria, pupil diameter \> 3 mm
- at least one risk of progression: optic disc (splinter) hemorrhage / cup to disc ratio (CDR) \> 0.7 / inter-eye asymmetry of CDR \>0.2 / notching of the optic disc /retinal nerve fibre layer (RNFL) defects / intraocular pressure( IOP) \>22 mmHg / central corneal thickness \< 520 µm / advanced visual field defect stage Aulhorn III / elder than 70 years
You may not qualify if:
- pregnancy, nursing
- diabetic retinopathy
- asthma
- HIV+ or AIDS
- history of epilepsy or significant psychiatric disease
- medications known to effect visual field sensitivity
- infections (e.g. keratitis, conjunctivitis, uveitis)
- severe dry eyes
- miotic drug
- amblyopia
- squint
- nystagmus
- albinism
- any ocular pathology, in either eye, that may interfere with the ability to obtain visual fields,disc imaging or accurate IOP readings
- keratoconus
- +6 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University Hospital Tuebingenlead
- Pfizercollaborator
Study Sites (1)
Centre for Ophthalmology, Institute for Ophthalmic Research
Tübingen, 72076, Germany
Related Publications (1)
Schiefer U, Pascual JP, Edmunds B, Feudner E, Hoffmann EM, Johnson CA, Lagreze WA, Pfeiffer N, Sample PA, Staubach F, Weleber RG, Vonthein R, Krapp E, Paetzold J. Comparison of the new perimetric GATE strategy with conventional full-threshold and SITA standard strategies. Invest Ophthalmol Vis Sci. 2009 Jan;50(1):488-94. doi: 10.1167/iovs.08-2229. Epub 2008 Dec 5.
PMID: 19060285BACKGROUND
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ulrich Schiefer, MD
Centre for Ophthalmology, Institute for Ophthalmic Research
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Prof. Dr. med.
Study Record Dates
First Submitted
February 16, 2010
First Posted
February 17, 2010
Study Start
November 1, 2008
Primary Completion
December 1, 2013
Study Completion
December 1, 2016
Last Updated
December 20, 2016
Record last verified: 2016-12